One of the most discussed and exciting CAR-T design (OR gate) developed thus far is the CARv3-TEAM therapy developed for GBM, that secretes a short-lived TCE against EGFR, thereby co-engaging bystander T cells alongside the cancer-specific anti-EGFRvIII CAR T cells (67). Here, EGFR is linked to cancer.